# Medical and pharmaceutical company financial reports

> Live situation record from CLSTR: https://clstr.news/situations/medical-and-pharmaceutical-company-financial-reports
> Updated: 2026-10-12T16:12:59.000Z. Sources: 4. Developments: 2.

Recent financial reports from the medical and pharmaceutical sectors show varying growth trajectories. 

Più Medical reported a 31% increase in pro-forma consolidated revenues for the first half of 2026, reaching 17.5 million euros. While the company's pro-forma net result rose to 603,000 euros, its consolidated adjusted EBITDA decreased from 2 million to 1.8 million euros, a margin contraction attributed to investments in recent acquisitions and central structure strengthening.

Valbiotis, a French laboratory focused on cardiometabolic health, reported a 130% increase in half-year revenue to €0.8 million. The company noted a cash position of €11.7 million and international expansion through agreements in China and the Middle East. However, Valbiotis has withdrawn its previously communicated financial ambitions for the 2026-2030 period.

## Timeline

### 2026-10-12: Valbiotis reports 130% revenue growth in first half of 2026

French cardiometabolic health laboratory Valbiotis reported a 130% increase in first-half 2026 revenue to €0.8 million and announced international expansion plans.

2 sources. https://clstr.news/cluster/valbiotis-reports-130-revenue-growth-in-first-half-of-2026

### 2026-10-05: Più Medical reports 31% revenue growth in first half of 2026

Più Medical reported a 31% increase in first-half 2026 revenues to 17.5 million euros, driven by pharmacy growth despite lower consolidated EBITDA margins due to integration investments.

2 sources. https://clstr.news/cluster/pi-medical-reports-31-revenue-growth-in-first-half-of-2026

---
Cite as: Medical and pharmaceutical company financial reports. CLSTR, https://clstr.news/situations/medical-and-pharmaceutical-company-financial-reports